Comparison of estimated blood loss during living kidney transplantation according to the number of double-filtration plasmapheresis
Background Plasmapheresis is an important preoperative desensitization treatment for ABO-incompatible living kidney transplantation. However, in cases with plasma exchange therapy (PET), it is necessary to consider the risks of perioperative bleeding and healthcare economic costs. This study investigated the association between intraoperative blood loss and the frequency of preoperative double-filtration plasmapheresis (DFPP) and explored the correlation between DFPP frequency and coagulation factors. Furthermore, the study examined the incidence of perioperative bleeding complications. Methods We enrolled 294 patients (205 men and 89 women) who underwent living kidney transplantation at our institution between January 2020 and March 2023, without PET or with only DFPP performed as PET. A single dose of rituximab (200 mg) was administered to ABO-incompatible living kidney transplant patients within 7 days before transplantation. In these patients, PET was performed until anti-blood group IgG and IgM antibody titers were reduced to 32 times or less. Results The intraoperative blood loss increased in accordance with the DFPP sessions. The amount of bleeding significantly increased when DFPP was performed ≥ 2 sessions. Considering this, we initiated serum fibrinogen level measurements from the middle of the study and observed that serum fibrinogen levels decreased in correlation with the number of DFPP sessions. Fibrinogen levels dropped to critical levels (< 100 mg/dL) after three sessions of DFPP. Within the entire cohort, four patients (1.4%) underwent post-transplantation hematoma removal surgery, and among them, three had received DFPP before transplantation. Conclusions The number of DFPP procedures was associated with the amount of bleeding and serum fibrinogen levels during living kidney transplantation..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Renal replacement therapy - 10(2024), 1 vom: 14. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yagisawa, Takafumi [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
ABO incompatible |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s41100-024-00544-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR05552415X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR05552415X | ||
| 003 | DE-627 | ||
| 005 | 20240415064611.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240415s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s41100-024-00544-0 |2 doi | |
| 035 | |a (DE-627)SPR05552415X | ||
| 035 | |a (SPR)s41100-024-00544-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Yagisawa, Takafumi |e verfasserin |0 (orcid)0000-0003-3174-3643 |4 aut | |
| 245 | 1 | 0 | |a Comparison of estimated blood loss during living kidney transplantation according to the number of double-filtration plasmapheresis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Background Plasmapheresis is an important preoperative desensitization treatment for ABO-incompatible living kidney transplantation. However, in cases with plasma exchange therapy (PET), it is necessary to consider the risks of perioperative bleeding and healthcare economic costs. This study investigated the association between intraoperative blood loss and the frequency of preoperative double-filtration plasmapheresis (DFPP) and explored the correlation between DFPP frequency and coagulation factors. Furthermore, the study examined the incidence of perioperative bleeding complications. Methods We enrolled 294 patients (205 men and 89 women) who underwent living kidney transplantation at our institution between January 2020 and March 2023, without PET or with only DFPP performed as PET. A single dose of rituximab (200 mg) was administered to ABO-incompatible living kidney transplant patients within 7 days before transplantation. In these patients, PET was performed until anti-blood group IgG and IgM antibody titers were reduced to 32 times or less. Results The intraoperative blood loss increased in accordance with the DFPP sessions. The amount of bleeding significantly increased when DFPP was performed ≥ 2 sessions. Considering this, we initiated serum fibrinogen level measurements from the middle of the study and observed that serum fibrinogen levels decreased in correlation with the number of DFPP sessions. Fibrinogen levels dropped to critical levels (< 100 mg/dL) after three sessions of DFPP. Within the entire cohort, four patients (1.4%) underwent post-transplantation hematoma removal surgery, and among them, three had received DFPP before transplantation. Conclusions The number of DFPP procedures was associated with the amount of bleeding and serum fibrinogen levels during living kidney transplantation. | ||
| 650 | 4 | |a ABO incompatible |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Double-filtration plasmapheresis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Fibrinogen |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Kidney transplantation |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Kanzawa, Taichi |e verfasserin |4 aut | |
| 700 | 1 | |a Fujiwara, Yuya |e verfasserin |4 aut | |
| 700 | 1 | |a Banno, Taro |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Ayaka |e verfasserin |4 aut | |
| 700 | 1 | |a Oki, Rikako |e verfasserin |4 aut | |
| 700 | 1 | |a Unagami, Kohei |e verfasserin |4 aut | |
| 700 | 1 | |a Hirai, Toshihito |e verfasserin |4 aut | |
| 700 | 1 | |a Omoto, Kazuya |e verfasserin |4 aut | |
| 700 | 1 | |a Hanafusa, Norio |e verfasserin |4 aut | |
| 700 | 1 | |a Ishida, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Takagi, Toshio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Renal replacement therapy |d BioMed Central, 2015 |g 10(2024), 1 vom: 14. Apr. |w (DE-627)SPR038245647 |w (DE-600)2866852-2 |x 2059-1381 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2024 |g number:1 |g day:14 |g month:04 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s41100-024-00544-0 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2024 |e 1 |b 14 |c 04 | ||